A method of making a functionalized fluorinated monomer for use in making oligomers and polymers that can be used to improve surface properties of polymer-derived systems, such as coatings. The method of making a functionalized fluorinated monomer includes reacting at least one fluorinated nucleophilic reactant, such as a fluorinated alcohol, with at least one compound containing at least one epoxide group. Other methods include reaction of a fluorinated alcohol with a cyclic carboxylic anhydride. In another embodiment, a method includes reacting a fluorinated mesylate, tosylate or triflate with an amine, alkoxide or phenoxide. In other embodiments, the method includes reacting a fluorinated alcohol with an alkyl halide, or reacting a fluorinated alkyl halide with an amine. The functionalized fluorinated monomers may be used as intermediates and reacted to modify the functional groups thereon. Further, the functionalized fluorinated monomers may be reacted to form polymers or oligomers, or with polymers or oligomers having functional groups to modify the polymer or oligomer through the functional group thereon.

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R.sup.1, R.sup.2, R.sup.6 and R.sup.6′ are independently selected from H, (C.sub.1-C.sub.8)alkyl, unsaturated (C.sub.2-C.sub.8)hydrocarbon, and (C.sub.3-C.sub.6)cycloalkyl, being these groups optionally substituted; R.sup.3 is hydrogen or halogen; R.sup.4 is selected from H, (C.sub.1-C.sub.8)alkyl, unsaturated (C.sub.2-C.sub.8)hydrocarbon, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.6-C.sub.12)aryl, and (C.sub.5-C.sub.12)heteroaryl, being these groups optionally substituted; and R.sup.5 is selected from (C.sub.3-C.sub.28)alkyl, unsaturated (C.sub.3-C.sub.28)hydrocarbon, (C.sub.6-C.sub.12)aryl, and (C.sub.5-C.sub.12)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications. ##STR00001##

The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R.sup.1, R.sup.2, R.sup.6 and R.sup.6′ are independently selected from H, (C.sub.1-C.sub.8)alkyl, unsaturated (C.sub.2-C.sub.8)hydrocarbon, and (C.sub.3-C.sub.6)cycloalkyl, being these groups optionally substituted; R.sup.3 is hydrogen or halogen; R.sup.4 is selected from H, (C.sub.1-C.sub.8)alkyl, unsaturated (C.sub.2-C.sub.8)hydrocarbon, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.6-C.sub.12)aryl, and (C.sub.5-C.sub.12)heteroaryl, being these groups optionally substituted; and R.sup.5 is selected from (C.sub.3-C.sub.28)alkyl, unsaturated (C.sub.3-C.sub.28)hydrocarbon, (C.sub.6-C.sub.12)aryl, and (C.sub.5-C.sub.12)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications. ##STR00001##

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins.